Alx Oncology Holdings Inc. (ALXO) intrinsic value & 10-year financials
Alx Oncology Holdings Inc. (ALXO) has a Graham intrinsic value of $65.99 per share. At $1.06 on Oct 17, 2026, the stock trades 98% below that value.
- Graham intrinsic value
- $65.99
- Share price (Oct 17, 2026)
- $1.06
- Price vs Graham value
- 98% below
- Market cap
- $56.9M
- Revenue (FY2025)
- —
- Revenue growth (9-yr CAGR)
- -24.4%
- ROIC (10-yr avg)
- -897.2%
- Free cash flow (FY2025)
- -$84.4M
ALXO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$101.7M | -$1.90 | -$84.4M | — | -155.7% |
| FY2024 | — | -$134.8M | -$2.58 | -$122.4M | — | -96.9% |
| FY2023 | — | -$160.8M | -$3.74 | -$131.6M | — | -82.6% |
| FY2022 | $0 | -$123.5M | -$3.03 | -$90.7M | — | -110.6% |
| FY2021 | $0 | -$83.5M | -$2.07 | -$68.8M | — | -6847.0% |
| FY2020 | $1.2M | -$45.7M | -$2.76 | -$38.3M | -3694.0% | 58.8% |
| FY2019 | $4.8M | -$19.2M | — | -$14.6M | -400.0% | 25.8% |
| FY2018 | $2.1M | -$13.7M | — | -$13.8M | -662.0% | 30.3% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
ALX ONCOLOGY HOLDINGS INC revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
ALX ONCOLOGY HOLDINGS INC has historically struggled to out-earn its cost of capital, averaging just -39.4% ROIC.
ALX ONCOLOGY HOLDINGS INC capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, ALX ONCOLOGY HOLDINGS INC is modeled at -24.4% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $65.99 per share.